15-methyl-8-nitrotetracyclo[6.6.2.0(2,7).0(9,14)]hexadeca-2,4,6,9,11,13-hexaene-15-carboxylic acid | 651042-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 15-methyl-8-nitrotetracyclo[6.6.2.0(2,7).0(9,14)]hexadeca-2,4,6,9,11,13-hexaene-15-carboxylic acid
• 英文别名: 9-Nitro-9,10-dihydro-11-methyl-9,10-ethanoanthracene-11-carboxylic acid；15-methyl-8-nitrotetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaene-15-carboxylic acid
• CAS: 651042-72-7
• 化学式: C₁₈H₁₅NO₄
• 分子量: 309.321
• InChiKey: HFLLJGIRHFYNNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  15-methyl-8-nitrotetracyclo[6.6.2.0(2,7).0(9,14)]hexadeca-2,4,6,9,11,13-hexaene-15-carboxylic acid 在 N,N-二甲基甲酰胺 草酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  WO2006/76702

  摘要：

  公开号：
• 作为产物：
  描述：

  甲基丙烯酸 、 9-硝基蒽 以 硝基苯 为溶剂， 生成 15-methyl-8-nitrotetracyclo[6.6.2.0(2,7).0(9,14)]hexadeca-2,4,6,9,11,13-hexaene-15-carboxylic acid 、 15-Methyl-1-nitrotetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaene-15-carboxylic acid
  参考文献：
  名称：

  Discovery of novel dihydro-9,10-ethano-anthracene carboxamides as glucocorticoid receptor modulators

  摘要：

  A series of dihydro-9,10-ethano-anthracene-11-carboxamides as novel glucocorticoid receptor modulators is reported. SAR exploration identified compounds from this series displaying a promising dissociation pro. le in discriminating between transrepression and transactivation activities. 17a is a partial agonist of GR-mediated transactivation which elicits potent and efficacious transrepression in reporter gene assays. A hypothetical binding mode is provided which accounts for the induction of functional activity by a bridgehead methyl group. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.03.006

文献信息

• Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
  申请人：Sheppeck James

  公开号：US20060154973A1

  公开（公告）日：2006-07-13

  The present invention relates to new class of non-steroidal compounds which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory- and immune-associated diseases, and have the structure including all stereoisomers thereof, tautomers thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein X is selected from N, O, and S; Y is N or CR 6 ; Z is a ring; and where R, R a , R b , R c , R d , R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  本发明涉及一类新的非甾体化合物，用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括肥胖、糖尿病、炎症和免疫相关疾病，并具有结构，包括其所有立体异构体、互变异构体或前药，或其药用可接受盐，其中X选自N、O和S；Y为N或CR6；Z为一个环；R、Ra、Rb、Rc、Rd、R1、R2、R3、R4和R5如本文所定义。还提供了包含所述化合物的药物组合物和治疗肥胖、糖尿病以及炎症或免疫相关疾病的方法。
• Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
  申请人：Dhar Murali T.G.

  公开号：US20070179189A1

  公开（公告）日：2007-08-02

  A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or (II): including a stereoisomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Q is selected from N, O, and S; Y is aryl or heteroaryl; Z is H, C 2-6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, or alkoxy; and A, B, R, R a , R b , R c and R d are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一类新型的非类固醇化合物，其在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病方面具有用处，包括肥胖症、糖尿病、炎症和免疫性疾病，并具有以下结构的式子(I)或(II)：包括其立体异构体、互变异构体、前药或药物可接受的盐，其中Q选择自N、O和S；Y为芳基或杂环芳基；Z为H、C2-6烷基、环烷基、杂环烷基、芳基、杂环芳基、卤素或烷氧基；A、B、R、Ra、Rb、Rc和Rd在此定义。还提供了包含该化合物的药物组合物和治疗肥胖、糖尿病和炎症或免疫相关疾病的方法。
• Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
  申请人：Bristol-Myers Squibb Co.

  公开号：US07361654B2

  公开（公告）日：2008-04-22

  The present invention relates to new class of non-steroidal compounds which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory- and immune-associated diseases, and have the structure including all stereoisomers thereof, tautomers thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein X is selected from N, O, and S; Y is N or CR6; Z is a ring; and where R, Ra, Rb, Rc, Rd, R1, R2, R3, R4, and R5 are as defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising such compounds.

  本发明涉及一类新型非甾体化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括肥胖症、糖尿病、炎症和免疫相关疾病，其结构包括所有立体异构体、互变异构体、前药或其药学上可接受的盐，其中X选择自N、O和S; Y为N或CR6; Z为环; R、Ra、Rb、Rc、Rd、R1、R2、R3、R4和R5的定义如本文所述。还提供了包含这些化合物的药物组合物和治疗肥胖症、糖尿病和炎症或免疫相关疾病的方法。
• MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Dhar T.G. Murali

  公开号：US20100113532A1

  公开（公告）日：2010-05-06

  A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or (II): including a stereoisomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Q is selected from N, O, and S; Y is aryl or heteroaryl; Z is H, C 2-6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, or alkoxy; and A, B, R, R a , R b , R c and R d are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一类新型非甾体化合物，其在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病中有用，包括肥胖症、糖尿病、炎症和免疫性疾病，其结构为公式（I）或（II）：包括其立体异构体、互变异构体、前药或其药学上可接受的盐，其中Q从N、O和S中选择；Y为芳基或杂环芳基；Z为H、C2-6烷基、环烷基、杂环烷基、芳基、杂环芳基、卤素或烷氧基；A、B、R、Ra、Rb、Rc和Rd在此定义。还提供了包含该化合物的制药组合物和治疗肥胖症、糖尿病和炎症或免疫相关疾病的方法。
• Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
  申请人：Bristol-Myers Squibb Company

  公开号：US08013004B2

  公开（公告）日：2011-09-06

  A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or (II): including a stereoisomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Q is selected from N, O, and S; Y is aryl or heteroaryl; Z is H, C2-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, or alkoxy; and A, B, R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一类新型非甾体化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括肥胖症、糖尿病、炎症和免疫性疾病，其结构为公式（I）或（II）：包括其立体异构体、互变异构体、前药或其药学上可接受的盐，其中Q选自N、O和S；Y为芳基或杂环芳基；Z为H、C2-6烷基、环烷基、杂环烷基、芳基、杂环芳基、卤素或烷氧基；A、B、R、Ra、Rb、Rc和Rd在此定义。还提供了包含上述化合物的制药组合物和治疗肥胖症、糖尿病和炎症或免疫相关疾病的方法。